Decreased intestinal acetylcholinesterase in early Parkinson disease: An <sup>11</sup>C-donepezil PET study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28100726.
- Also identified by DOI 10.1212/WNL.0000000000003633.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate systemic levels of acetylcholinesterase in early Parkinson disease (PD) with <sup>11</sup>C-donepezil PET, a potential marker of parasympathetic innervation. This was a cross-sectional study with 19 patients with early-stage PD (disease duration 1.5 ± 0.6 years) and 16 age-matched controls who had clinical assessments, olfaction tests, and <sup>11</sup>C-donepezil PET to measure acetylcholinesterase density in peripheral organs. The patients with PD showed significantly reduced <sup>11</sup>C-donepezil uptake in the small intestine (-14%, <i>p</i> = 0.018), colon (-22%, <i>p</i> < 0.001), and kidneys (-14%, <i>p</i> = 0.028). No difference in myocardial or pancreatic acetylcholinesterase levels was seen. We found significantly decreased <sup>11</sup>C-donepezil signal in the intestine and kidneys of patients with early PD, suggesting that parasympathetic denervation is present early in the disease course.
Medical subject headings
- Acetylcholinesterase
- Intestines
- Parkinson Disease
- Positron-Emission Tomography